Clinical resistance to topoisomerase-targeted drugs
- PMID: 9748627
- DOI: 10.1016/s0167-4781(98)00141-9
Clinical resistance to topoisomerase-targeted drugs
Abstract
This review describes topoisomerase (topo)-mediated drug resistance and topo expression in human tissues and cancers. In some in vitro studies a relation has been observed between topo I, IIalpha or IIbeta expression and sensitivity to topo inhibitors. Drug resistance to topo inhibitors may, however, be multifactorial. Several topo inhibitors are substrates for drug membrane transporters. As most topo inhibitors are cell cycle specific, disturbances in cell cycle regulation can also confer resistance, and downstream events following DNA damage induced by topo inhibitors may be involved in regulating cell death or survival. Several studies in patient specimens have shown a relation between topo IIalpha expression and the proliferative state of the tumor, higher topo IIalpha levels being seen in more highly proliferating tumor types. In contrast, topo IIbeta appears to be expressed in both proliferating and quiescent cells. Furthermore, higher topo I levels were observed in some tumors when compared to their normal counterparts. In some studies a reduced topo IIalpha level was seen in samples taken after chemotherapy treatment, as compared with specimens prior to treatment. No unequivocal relation was observed, however, between expression or activity of the topo genes and response to chemotherapy; nonetheless only a few studies have properly addressed this question. This review summarizes the results of the clinical studies performed so far, and analyzes the critical issues in performing studies on patient material.
Similar articles
-
An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.Biochem Pharmacol. 2000 Sep 15;60(6):817-21. doi: 10.1016/s0006-2952(00)00402-0. Biochem Pharmacol. 2000. PMID: 10930536
-
Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.Cancer Res. 1996 Jun 1;56(11):2573-83. Cancer Res. 1996. PMID: 8653700
-
Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.Cancer Chemother Pharmacol. 1998;41(5):353-60. doi: 10.1007/s002800050751. Cancer Chemother Pharmacol. 1998. PMID: 9523730
-
Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.Curr Med Chem. 2010;17(35):4270-90. doi: 10.2174/092986710793361252. Curr Med Chem. 2010. PMID: 20939813 Review.
-
Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs.Adv Pharmacol. 1994;29B:127-43. doi: 10.1016/s1054-3589(08)61135-7. Adv Pharmacol. 1994. PMID: 8996605 Review.
Cited by
-
Modulation of topoisomerase IIα expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide.Biochim Biophys Acta Gene Regul Mech. 2017 May;1860(5):617-629. doi: 10.1016/j.bbagrm.2016.10.005. Epub 2016 Oct 24. Biochim Biophys Acta Gene Regul Mech. 2017. PMID: 27750031 Free PMC article.
-
Metnase mediates chromosome decatenation in acute leukemia cells.Blood. 2009 Aug 27;114(9):1852-8. doi: 10.1182/blood-2008-08-175760. Epub 2009 May 20. Blood. 2009. PMID: 19458360 Free PMC article.
-
Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer.Neoplasia. 2006 Jan;8(1):9-17. doi: 10.1593/neo.05517. Neoplasia. 2006. PMID: 16533421 Free PMC article.
-
Inhibition of DNA Topoisomerase Type IIα (TOP2A) by Mitoxantrone and Its Halogenated Derivatives: A Combined Density Functional and Molecular Docking Study.Biomed Res Int. 2016;2016:6817502. doi: 10.1155/2016/6817502. Epub 2016 Feb 15. Biomed Res Int. 2016. PMID: 27088089 Free PMC article.
-
Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions.BMC Mol Biol. 2007 May 20;8:36. doi: 10.1186/1471-2199-8-36. BMC Mol Biol. 2007. PMID: 17511886 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials